Live MediSum Demo

This meta-analysis pooled six randomized, placebo-controlled phase III trials of oral systemic monotherapies in previously treated metastatic colorectal cancer (n=3,277) and compared outcomes versus placebo. Random-effects estimates showed a median overall survival benefit of 1.86 months (95% CI, 1.30–2.42), HR for OS 0.69 (95% CI, 0.64–0.76), and a 12-month RMST difference of 1.25 months (95% CI, 0.69–1.82); for PFS the median improvement was 0.97 months (95% CI, 0.28–1.66) with HR 0.38 (95% CI, 0.30–0.47) and 12-month RMST difference 1.90 months (95% CI, 1.41–2.39). The authors conclude that oral systemic monotherapy produces small but measurable survival gains versus no active therapy in later-line mCRC when multiple survival measures are considered.

This review covers rare gynecologic tumors—gestational trophoblastic neoplasia, ovarian germ cell tumors, and ovarian clear-cell carcinoma—summarizing clinical features, staging, and current treatments which largely follow ovarian cancer paradigms while increasingly incorporating targeted therapies. It notes gestational trophoblastic tumors are usually curable even when widely metastatic, whereas ovarian clear-cell carcinoma is characterized by intrinsic chemoresistance and distinct molecular features, prompting movement toward biologically aligned strategies using molecular selection and microenvironmental modulation for future therapeutic development.

This systematic review identified 14 preclinical in vivo glioblastoma studies testing various STING agonists delivered by intracranial injection, hydrogels, or nanoparticles and found consistent immune effects including increased CD8+ T‑cell and NK‑cell infiltration and repolarization of tumor-associated macrophages toward pro‑inflammatory phenotypes. Several studies reported prolonged survival and occasional long‑term tumor clearance, and some demonstrated synergistic effects when STING agonists were combined with immune checkpoint blockade or radiotherapy, while authors note translational challenges related to model limitations and uncertain cell‑type–specific STING effects in the brain.